Related references
Note: Only part of the references are listed.Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis
Aart C. Strang et al.
ATHEROSCLEROSIS (2013)
Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis
Iris Navarro-Millan et al.
CURRENT OPINION IN RHEUMATOLOGY (2013)
Small molecular compounds in development for rheumatoid arthritis
Ronald F. van Vollenhoven
CURRENT OPINION IN RHEUMATOLOGY (2013)
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature
Archana Jain et al.
IMMUNOTHERAPY (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Back to the future: oral targeted therapy for RA and other autoimmune diseases
John J. O'Shea et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
The problem of choice: current biologic agents and future prospects in RA
Ernest H. Choy et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
The many faces of Janus kinase
Matthew M. Seavey et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Apostolos Kontzias et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Novel small-molecular therapeutics for rheumatoid arthritis
Roy Fleischmann
CURRENT OPINION IN RHEUMATOLOGY (2012)
Persistence and compliance of medications used in the treatment of osteoporosis - analysis using a large scale, representative, longitudinal German database
Volker Ziller et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance
Ilias Stagakis et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis
Soner Senel et al.
CLINICAL RHEUMATOLOGY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Go upstream, young man'': lessons learned from the p38 saga
D. Hammaker et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
Benazir Saleem et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
Xin An et al.
LEUKEMIA RESEARCH (2010)
Targeting non-malignant disorders with tyrosine kinase inhibitors
Friedrich Grimminger et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The role of endothelial function and its assessment in rheumatoid arthritis
Faisel Khan et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Michael E. Weinblatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The SYK tyrosine kinase: a crucial player in diverse biological functions
Attila Mocsai et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients
C. Popa et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Role for TNF in atherosclerosis? Lessons from autoimmune disease
Gayle E. McKellar et al.
NATURE REVIEWS CARDIOLOGY (2009)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Translation of the Philadelphia chromosome into therapy for CML
Brian J. Druker
BLOOD (2008)
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis
Andreas J. Flammer et al.
CIRCULATION (2008)
Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years:: evidence for different types of response
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis
J. Braun et al.
ARTHRITIS AND RHEUMATISM (2008)
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis
Calin Popa et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Emerging oral therapies for multiple sclerosis
B. A. Cohen et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy -: Results from the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2007)
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis - Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety concerns on the development of novel therapeutic drugs
Caroline Ospelt et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Src-family kinases: rheostats of immune cell signaling
CA Lowell
MOLECULAR IMMUNOLOGY (2004)
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
J Cools et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Sticky issue of adherence
SM Sawyer et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Development of matrix metalloproteinase inhibitors in cancer therapy
M Hidalgo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
